Through its unique collaboration with the UMC Utrecht and its Athero-Express study, Cavadis has access to a state-of-the-art biomarker discovery platform, enabling the company to identify and validate novel biomarkers predictive for cardiovascular diseases.
Read more

In the discovery phase we identified a panel of differentially expressed exosomal biomarkers. The predictive power of this panel for adverse cardiovascular events is confirmed in large validation studies.
Read more

Cavadis recognizes the increasing need for novel biomarkers to assess cardiovascular risk and acknowledges the rigourous requirements to prove their value in clinical practice. Recently the American Heart Association (AHA) published a set of guidelines proposing standards for the critical appraisal of novel biomarkers.
Read more

Our mission
Cavadis is a Dutch biomedical company active in the field of cardiovascular risk assessment. The company's mission is to identify patients at risk of developing heart attacks and strokes. Our ultimate goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.
read more